RA Capital has led a $100m series B round for Ventus Therapeutics, which is linked to multiple universities.
Ventus Therapeutics, a US-based small molecule drug developer, completed a $100m series B round yesterday led by investment manager RA Capital Management.
GV, a corporate venture capital subsidiary of internet and technology group Alphabet, also took part in the round, as did Alexandria Venture Investments, the VC arm of real estate investment trust Alexandria Real Estate Equities.
BVF Partners, Casdin Capital, Cormorant Asset Management, Fonds de solidarité FTQ and Versant Ventures filled out the round.
Founded in…
